| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 01/17/2006 | US6987092 Indigoid bisindole derivatives |
| 01/17/2006 | US6987005 Where the human SNORF33 receptor has the amino acid sequence SEQ ID NO: 6; encoded by ATCC deposited plasmids; activated by either tyramine, tryptamine, or beta -phenyl-ethylamine; vectors; cells; membranes; nervous system disorders |
| 01/17/2006 | US6986984 Use of defibrinated blood for manufacture of a hemoglobin-based oxygen carrier |
| 01/17/2006 | US6986905 Pharmaceutical compositions for treating and saving and the method for the preparation thereof |
| 01/12/2006 | WO2006005058A2 Polymer-factor ix moiety conjugates |
| 01/12/2006 | WO2006003495A1 Substituted heteroaryl- and phenylsulfamoyl compounds |
| 01/12/2006 | US20060009513 Nebivolol and its metabolites in combination with nitric oxide donors, compositions and methods of use |
| 01/12/2006 | US20060009482 Screening method for identifying compounds that selectively induce interferon alpha |
| 01/12/2006 | US20060009402 Engineered RNA precursors encoded in plasmids and/or other vectors; simple, low cost technique utilizing DNA molecule production; host cells, transgenes |
| 01/12/2006 | US20060009397 New use |
| 01/12/2006 | US20060009383 Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same |
| 01/12/2006 | DE102004030987A1 Ortho-substituierte (3-Hydroxyphenyl)-essigsäure-benzyliden-hydrazide Ortho-substituted (3-hydroxyphenyl) -acetic acid benzylidene-hydrazide |
| 01/12/2006 | CA2573193A1 Substituted heteroaryl- and phenylsulfamoyl compounds |
| 01/12/2006 | CA2572872A1 Tissue factor production inhibitor |
| 01/12/2006 | CA2572163A1 Pyrazole derivatives |
| 01/12/2006 | CA2571292A1 Polymer-factor ix moiety conjugates |
| 01/12/2006 | CA2570048A1 Combination therapies employing platelet aggregation drugs |
| 01/11/2006 | EP1614680A2 Process for preparing 2-iminopyrrolidine derivatives |
| 01/11/2006 | EP1614678A2 Sulfur substituted sulfonylaminocarboxylic acid N-heteroarylamides, their preparation, their use and pharmaceutical preparations comprising them |
| 01/11/2006 | EP1614675A2 Amino acids with affinity for the alpha-2-delta protein |
| 01/11/2006 | EP1613319A2 Substituted phenyl acetamides and their use as protease inhibitors |
| 01/11/2006 | EP1497283A4 Maleic acid salt of(2s)-n-(5(amino(imino)methyl)-2-thienyl)methyl-1-(2r)-2-((2r)-2-((carboxymethyl)amino)3,3-diphenylpropanoyl)-2-pyrrolidine carboxamide and a process for |
| 01/11/2006 | EP1469887A4 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids |
| 01/11/2006 | EP1340753B1 Carbamate derivatives, process for producing the same and use thereof |
| 01/11/2006 | EP1133291B1 Cyclic polyamines for treating thrombocytopenia |
| 01/11/2006 | EP1131315B1 Polyhydroxylated heterocyclic derivatives as anti-coagulants |
| 01/11/2006 | EP1037632B1 Benzothiazole protein tyrosine kinase inhibitors |
| 01/11/2006 | EP0787142B1 Neurturin and related growth factors |
| 01/11/2006 | EP0782616B1 Therapeutic grade thrombin production and products |
| 01/11/2006 | CN1718735A Production of polyglutamic acid using na bean bacillus solid fermentation and its product application |
| 01/11/2006 | CN1718221A Compounding traditional Chinese medicine for dissolving stasis and hemostasis, and its prepn. method |
| 01/11/2006 | CN1235914C Polysaccharides with antithrombotic activity comprising at least a covalent bono with biotin or a biotin derivative |
| 01/11/2006 | CN1235900C Thioether substituted imidazoquinolines |
| 01/11/2006 | CN1235638C Activated protein C formulations |
| 01/11/2006 | CN1235615C Chinese medicinal preparation for treating coronary heart disease, cerebral thrombus and cerebral infarct and preparing process thereof |
| 01/11/2006 | CN1235583C Benzimidazole derivatives as therapeutic agents |
| 01/11/2006 | CN1235567C Cationic liposome delivery of taxanes to angiogenic blood vessels |
| 01/10/2006 | US6984651 Piperidine amides as modulators of chemokine receptor activity |
| 01/10/2006 | US6984648 TNF (tumor necrosis factor); for treating conditions such as rheumatoid and osteoarthritis, corneal, epidermal or gastric ulceration; tumor metastasis or invasion; periodontal disease and bone disease |
| 01/10/2006 | US6984641 Carboline derivatives as PDE5 inhibitors |
| 01/10/2006 | US6984624 Composition containing an iron complexing protein and a precursor of nitrogen monoxide metabolism and/or a chemical donor of nitrogen monoxide and uses thereof |
| 01/10/2006 | CA2406745C A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
| 01/05/2006 | WO2006000007A1 Use of peptides derived from the a alpha or b beta chain of human fibrinogen for the treatment of shock |
| 01/05/2006 | WO2003031598A3 Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use |
| 01/05/2006 | US20060004084 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors |
| 01/05/2006 | US20060004080 Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof a JNK inhibitors and compositions and methods related thereto |
| 01/05/2006 | US20060004077 Inhibiting class II MHC-mediated activation of T cells; peptidomimetics of given sequence which include a Gpg (guanylpiperidyl glycine) unit; rheumatoid arthritis and/or multiple sclerosis; e.g. Ac-Cha-Gpg-Tic-Nle-NHCH2CH2Ph (Cha=cyclohexylalanine, Tic=3-carboxyisoquinoline, Nle=norleucine) |
| 01/05/2006 | US20060004062 Compounds for inhibiting insulin secretion and methods related thereto |
| 01/05/2006 | US20060004025 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors |
| 01/05/2006 | US20060003987 Compounds and their uses |
| 01/05/2006 | US20060003975 Combination of an aldosterone receptor antagonist and an HMG CoA reductase inhibitor |
| 01/05/2006 | US20060003923 Stability, reduced toxicity; covalently linked imidazole functionality |
| 01/05/2006 | US20060003922 Spinner preparation machine and cavity resonator |
| 01/05/2006 | US20060003921 Pharmaceutical preparation comprising vWF propeptide |
| 01/05/2006 | US20060003025 comprising from 1300 to 1500 mg/l of Na+, from 4500 to 6500 mg/l of K+, from 50 to 1300 mg/l of Mg++, from 20 to 350 mg/l of ca++, from 4000 to 6000 mg/l of Cl-, a pH of from 4-9, and an osmolality of from 150-700 mOsm/kg; for treating and cleaning the eye |
| 01/05/2006 | DE102004027821A1 Benzimidazole, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel Benzimidazoles, process for their preparation and their use as medicaments |
| 01/05/2006 | CA2570499A1 Method for producing 4-(benzimidazolylmethylamino)-benzamidines |
| 01/05/2006 | CA2544676A1 Use of peptides derived from the a alpha or b beta chain of human fibrinogen for the treatment of shock |
| 01/04/2006 | EP1611885A1 Use of an inducing agent for the treatment of blood, viral and cellular disorders |
| 01/04/2006 | EP1409455B1 Prostaglandin analogues-as ep4 receptor agonists |
| 01/04/2006 | EP1397153A4 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
| 01/04/2006 | EP1294390B1 The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotection from glutamate toxicity |
| 01/04/2006 | EP1250422B1 Myeloid colony stimulating factor and uses thereof |
| 01/04/2006 | EP1202744B1 PRODUCTION OF rhPBGD |
| 01/04/2006 | CN1714874A Absorptive bone hemostatic agent |
| 01/04/2006 | CN1714854A Hemostatic |
| 01/04/2006 | CN1714849A Maluoning powder injection for injection and its preparing method |
| 01/04/2006 | CN1714810A Drugs, foods, drinks and feeds containing cocoa component |
| 01/04/2006 | CN1714808A Method for preparing blood flow cutting off dispersing tablet |
| 01/04/2006 | CN1234731C Human erythropoietin Fc fusion protein with high bioactivity |
| 01/04/2006 | CN1234708C Novel imidazotriazinones and the use thereof |
| 01/04/2006 | CN1234688C 3-arylindole and their use as cb2 receptor agonists |
| 01/04/2006 | CN1234417C Pharmaceutical compositions comprising dendritic cells for immunotherapy of automimmune disease and treatment methods using the same |
| 01/04/2006 | CN1234394C Medicine for treating chronic and refractory primary thrombocytopenic purpura |
| 01/04/2006 | CN1234390C Medicine for treating hydrops and hydroncus and preparing method thereof |
| 01/04/2006 | CN1234367C Arylazo-substituted imidazole for treatment of stress urinary incontinence |
| 01/03/2006 | US6982335 Synthesis of substituted thiazoline carboxylic acids |
| 01/03/2006 | US6982270 1-Phenyl-2-oxo-3,4-dihydro-6-phenylaminoquinazoline for example; cytokine suppressive anti-inflammatory drugs; combination therapy |
| 01/03/2006 | US6982253 Liquid formulation of decitabine and use of the same |
| 01/03/2006 | CA2176117C Generation of high titers of recombinant aav vectors |
| 12/29/2005 | WO2005123735A1 Process for producing evodiamine-containing composition |
| 12/29/2005 | WO2005123651A1 L-2-(α-HYDROXYPENTYL)BENZOATES, THE PREPARATION AND THE USE THEREOF |
| 12/29/2005 | WO2005123063A1 Compositions for urinary dysfunction and edema containing decursin and/or decursinol angelate, or angelica extract containing decursin and /or decursinol angelate |
| 12/29/2005 | WO2004062582A3 Combination therapy for anticoagulation |
| 12/29/2005 | WO2003012122A3 Crystallized structure of type iv collagen nc1 domain hexamer |
| 12/29/2005 | US20050289658 System for regulating in vivo the expression of a transgene by conditional inhibition |
| 12/29/2005 | US20050288487 Human mast cell-expressed membrane proteins |
| 12/29/2005 | US20050288376 Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides |
| 12/29/2005 | US20050288366 Administering N-(4-carboxybutyl)-N-(p-carboxybenzyl)-benzyl- or phenethyl-amine derivatives: 4-({(4-Carboxybutyl)[3-(4-cyclohexylphenoxy)benzyl]amino}methyl)-benzoic acid; stimulate soluble guanylate cyclase also via a novel mechanism of action which takes place without involvement of the heme group |
| 12/29/2005 | US20050288357 e.g. 4-(2-{2-[4-hydroxy-4-(1-propylcyclobutyl)but-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoic acid; antiinflammatory, hypotensive, antiulcer agent |
| 12/29/2005 | US20050288350 Useful in female hormone replacement therapy and as modulators of fertility; therapy of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flashes, mood disorders, meningiomas, cancer; 6-(bis-2,2,2-Trifluoroethyl)amino-4-trifluoromethylcoumarin |
| 12/29/2005 | US20050288340 Substituted heteroaryl- and phenylsulfamoyl compounds |
| 12/29/2005 | US20050288337 Novel compounds |
| 12/29/2005 | US20050288320 Induce biosymthesis of cytokines, interferons, tumor necrosis factor; antitumor agents; viricides; chemical intermediates |
| 12/29/2005 | US20050288305 N-biarylmethyl aminocycloalkanecarboxamide derivatives |
| 12/29/2005 | US20050288263 2-(&agr;-Hydroxypently) benzoate and its preparation and use |
| 12/29/2005 | US20050288254 Treating sepsis or septic shock by administering 1-stearoyl, 1-palmitoyl-, 1-myristoyl- lysophosphatidylcholine, or 1-oleoyllysophosphatidylcholine or sphingosylphosphorylcholine. |
| 12/29/2005 | US20050288235 Sodium chloride; dextran, carboxymethyl starch, sodium alginate, pentahydroxyethyl starch, gelatin derivatives or pectin; NaHCO3, KCl, MgSO4, CaCl, calcium gluconate, calcium lactate, sodium lactate, and/or Tris buffer; total Na ion does not exceed equivalent concentration of 6.9% (w/v); traumatic shock |
| 12/29/2005 | US20050288220 Erythropoietin with high specific activity |
| 12/29/2005 | US20050287605 Caspase 3 inhibitors |